Search for: All records

This study reports the introduction of alkyl carbon pronucleophiles to sulfur fluoride exchange (SuFEX) exhibited by the synthesis of aryl alkyl sulfones. Parallel medicinal chemistry (PMC) is exemplified with amides, and late-stage functionalization is demonstrated with a drug scaffold. 

Enantiodivergence is an important concept in asymmetric catalysis that enables access to both enantiomers of a product relying on the same chiral source as reagent. This strategy is particularly appealing as an alternate approach when only one enantiomer of the required chiral ligand is readily accessible but both enantiomers of the product are desired. Despite the potential significance, general catalytic methods to effectively reverse enantioselectivity by changing an achiral reaction parameter remain underdeveloped. Herein we report our studies focused on elucidating the origin of metal-controlled enantioselectivity reversal in Lewis acid-catalysed Michael additions. Rigorous experimental and computational investigations reveal that specific Lewis and Brønsted acid interactions between the substrate and ligand change depending on the ionic radius of the metal catalyst, and are key factors responsible for the observed enantiodivergence. This holds potential to further our understanding of and facilitate the design of future enantiodivergent transformations. 

Abstract A 14‐step synthesis of (+)‐cochlearol B is reported. This renoprotective meroterpenoid features a unique core structure containing a densely substituted cyclobutane ring with three stereocenters. Our strategy employed an organocatalytic Kabbe condensation in route to the key chromenyl triflate. A subsequent Catellani reaction incorporated the remaining carbon atoms featured in the skeleton of cochlearol B. An ensuing visible‐light‐mediated [2+2] photocycloaddition closed the cyclobutane and formed the central bicyclo[3.2.0]heptane core. Notably, careful design and tuning of the Catellani and photocycloaddition reactions proved crucial in overcoming undesired reactivity, including cyclopropanation reactions and [4+2] cycloadditions.